Free Consultation

Mass Torts

Tepezza Lawsuit: Hearing Loss Claims After Thyroid Eye Disease Treatment

You took Tepezza hoping for relief from thyroid eye disease. What you got instead? Ringing ears. Muffled sounds. Maybe even permanent hearing loss that no one warned you about.

Click for Free Case Evaluation

Get Your Free Case Review

Find out if you qualify for compensation and learn your next steps – no cost, no obligation, just expert legal guidance.

Disclaimer: By submitting the form above and checking the consent box, you agree to our conditions and privacy policy and permit Ethen Ostroff Law to contact you via text messages, phone calls. Standard message rates may apply.


Get Your Free Case Review

Find out if you qualify for compensation and learn your next steps – no cost, no obligation, just expert legal guidance.

Disclaimer: By submitting the form above and checking the consent box, you agree to our conditions and privacy policy and permit Ethen Ostroff Law to contact you via text messages, phone calls. Standard message rates may apply.


At Ethen Ostroff Law, we’re talking to people just like you—people who followed their doctor’s advice only to discover Tepezza’s manufacturer may have hidden known hearing risks. Now, patients nationwide are filing lawsuits to recover what they’ve lost.

Here’s what we know:

  • Studies show Tepezza causes hearing damage far more often than originally claimed 
  • Many patients report their warnings came too late—after the damage was done 
  • Lawsuits allege Horizon Therapeutics knew about these risks but didn’t disclose them

If you’re struggling with hearing loss after Tepezza treatment, you may be able to file a Tepezza lawsuit to hold the manufacturer accountable. Every case is different, but one thing remains constant: you deserve answers and accountability. Continue reading to learn more about what happened, whether you have a case, the Tepezza litigation process, and what compensation you’re entitled to.

Tepezza for Thyroid Eye Disease

Tepezza is a prescription infusion medication used to treat thyroid eye disease or TED. TED is a condition where the tissue behind the eyes swells and pushes the eyes forward. That pressure can cause pain, pressure, vision issues, and changes to how the eyes look or move.

The drug was approved by the FDA in early 2020 and is made by Horizon Therapeutics. It’s currently the only medication approved specifically for thyroid eye disease in the U.S. Treatment usually involves eight infusions, spaced three weeks apart. The idea is to reduce inflammation and stop the swelling from getting worse.

Thyroid Eye Disease

Thyroid eye disease, also called TED, is an autoimmune issue that causes swelling in the muscles and tissues behind the eyes. That swelling can push the eyes outward, make them feel sore or tight, and even change how your eyes move or line up. Some people get puffy eyelids or feel pressure around their eyes that just doesn’t go away.

It’s usually tied to Graves’ disease, another autoimmune disorder which makes the thyroid overactive. But TED doesn’t always follow the rules. It can still happen even if your thyroid levels are normal or low. Women tend to get it more often than men, and it can show up at almost any age.

Common Symptoms of Thyroid Eye Disease

Thyroid eye disease doesn’t always show up the same way for everyone. For some, it starts slow, with a little swelling or dryness. For others, it hits harder, with noticeable changes to how the eyes feel, move, or even look.

Here are the symptoms people with TED most often report:

  • Eyes that bulge or appear more “stared out” than usual 
  • Swelling or puffiness around the eyes, especially in the morning 
  • Red or irritated eyes 
  • Eyelids that pull back, showing more of the white part of the eye 
  • Trouble fully closing your eyes 
  • A gritty, dry, or scratchy feeling, like something’s always stuck in your eye 
  • Eyes that won’t stop watering 
  • Pain behind or around the eyes, sometimes sharp, sometimes dull 
  • Blurred vision or seeing double 
  • Eyes that feel stuck or don’t move smoothly when you look up or to the side 
  • Extra sensitivity to light 
  • Bags or dark circles under the eyes 
  • Eyes that don’t line up properly (eye misalignment) 
  • In more serious cases, vision that dims or starts to fade (this is rare but serious)

You might not have all of these, and some symptoms may come and go, but if you’re noticing changes, especially more than one at a time, it’s worth paying attention to. Left untreated, TED can lead to more serious problems down the road.

Get Free Consultation

Treatment Options for Thyroid Eye Disease

There’s no one-size-fits-all approach to treating TED. What works for one person might not be right for another—it really depends on how severe the symptoms are and whether the inflammation is still active. Treatment usually involves a mix of managing symptoms, calming the immune system, and, if needed, correcting damage through surgery.

Depending on how bad it is, here’s how doctors usually treat TED:

Everyday symptom relief: For people with mild TED, the goal is to make the eyes more comfortable and prevent further irritation. This can include:

  • Artificial tears or eye gels 
  • Lubricating ointments at night 
  • Cold compresses 
  • Sleeping with your head elevated 
  • Prism glasses or eye patches for double vision 
  • Emotional support through counseling or support groups

Lifestyle changes: Two key things can make a big difference in slowing TED down:

  • Keeping your thyroid hormone levels stable with proper treatment 
  • Quitting smoking

Supplements for early stages: For people with mild, active TED—especially in areas with low selenium in the diet—selenium supplements (typically 100 mcg twice a day) may help reduce symptoms.

Medication for moderate to severe TED: When symptoms are more intense or the disease is active, doctors may use medications to calm inflammation and reduce eye problems:

  • Steroids (usually IV) to reduce inflammation quickly 
  • Orbital radiation (sometimes used with steroids) to target the tissue around the eyes 
  • Immune-modulating drugs like Tepezza, which is FDA-approved and helps reduce eye bulging and double vision 
  • Other drugs like tocilizumab or mycophenolate may be used when steroids don’t work

Surgery (if needed): Once the inflammation has settled, some people still have lasting issues—like bulging eyes or double vision. In those cases, surgery may be an option:

  • Orbital decompression to relieve pressure and bring the eyes back into position 
  • Eye muscle surgery to fix double vision 
  • Eyelid surgery to help the eyes close properly or reduce retraction

Hearing Problems Reported During Tepezza Trials

Tepezza wasn’t on the market long before hearing issues started to raise red flags. During early clinical trials, a few patients began reporting ear-related symptoms, like ringing, sensitivity to sound, and even hearing loss. While these cases were small in number, they happened early enough to get researchers’ attention.

In a Phase 2 trial from 2017, about 7% of patients taking Tepezza reported hearing problems, including tinnitus and hearing loss. One patient didn’t notice hearing issues until after the treatment ended. That was enough for researchers to start watching more closely.

By the time the Phase 3 trial rolled out in 2020, the rate had gone up. Around 10% of patients getting Tepezza reported hearing-related side effects. Symptoms included:

  • Ringing in the ears (tinnitus) 
  • Sensitivity to sound 
  • Trouble hearing clearly 
  • A strange echo effect when speaking 
  • Eustachian tube dysfunction

One patient even experienced deafness. These early trials confirmed what many feared—Tepezza could affect hearing, and not all cases went away on their own.

In follow-up studies done outside of clinical trials, the numbers were worse. Once researchers started using formal hearing tests, they found a much higher rate of hearing problems:

  • Stanford Study (Sears et al., 2022): Out of 27 patients, 22 reported new hearing symptoms after getting Tepezza. Only six had full audiology testing, but five of them confirmed hearing loss.
  • Belinsky Study (2022): Four out of 28 Tepezza patients were diagnosed with hearing loss confirmed through hearing exams. The study warned that side effects ranged from mild and temporary to potentially permanent.
  • Douglas Study (2024): In a group of 52 patients, five experienced measurable hearing decline after Tepezza. Most of them had pre-existing ear issues, suggesting that people with prior hearing trouble may be more vulnerable.
  • Keen Study (2024): Among 22 patients, half had a drop in hearing, especially in the higher ranges. Older adults were hit the hardest.

Together, these studies suggest hearing loss may be much more common than early trials showed, especially when doctors test hearing before and after treatment.

Patient experiences and clinical studies aren’t the only warning signs. Reports sent directly to the FDA show a consistent pattern.

Between early 2020 and early 2023, there were 296 reports of ear-related issues tied to Tepezza in the FDA’s Adverse Event Reporting System (FAERS). Of those:

  • 149 cases involved hearing loss 
  • 194 reported tinnitus, vertigo, or ear fullness 
  • Some people had more than one symptom

One 2024 review found that hearing problems were reported far more often with Tepezza than with most other drugs in the FAERS database. Older patients, especially those 65 and up, were more likely to experience these side effects.

Early warnings were there, but they were easy to miss. What started as a small signal in clinical trials has now grown into a serious concern for many patients. More recent studies suggest that Tepezza hearing loss may be more common, more severe, and longer-lasting than the drug’s original data suggested, especially for older adults or those with past ear problems.

Hearing-Related Side Effects Reported After Tepezza Treatment

More and more patients are coming forward with serious hearing issues after receiving Tepezza infusions. For some, the symptoms started partway through treatment. For others, the damage didn’t show up until weeks or even months later.

The types of hearing problems reported vary from person to person, but here are the most commonly documented side effects:

  • Hearing loss (temporary, partial, or permanent) 
  • Tinnitus (ringing or buzzing in the ears) 
  • Muffled hearing (sounds may feel distant or unclear) 
  • Ear pressure or a plugged sensation 
  • Autophony (when your own voice sounds unusually loud or echoey) 
  • Sensorineural hearing loss (SNHL), a more serious type of damage to the inner ear 
  • Patulous Eustachian tube dysfunction, where the ear canal doesn’t close properly 
  • Decreased clarity when listening to speech

Many of these symptoms show up gradually, and some people didn’t realize how much their hearing had changed until someone else pointed it out or until a formal hearing test confirmed it.

What’s especially troubling is that for some patients, these issues didn’t go away after the infusions stopped. In fact, some cases of Tepezza side effects hearing loss appear to be permanent. A number of patients now rely on hearing aids to cope with long-term damage.

How Tepezza Might Be Damaging Hearing

There’s still a lot doctors don’t know about why Tepezza causes hearing problems, but one thing’s clear: it’s happening more often than expected.

Tepezza works by blocking something called IGF-1R, a protein involved in inflammation. That’s how it helps reduce the swelling behind the eyes in thyroid eye disease. But that same protein also plays a role in how the inner ear works.

So, when Tepezza blocks IGF-1R, it might be doing more than just calming the eyes. It could also be messing with the delicate systems that control hearing. Some researchers think it may trigger inflammation inside the ear or disrupt the balance in areas like:

  • The cochlea (where sound gets processed) 
  • The auditory nerve (which sends sound to the brain) 
  • The Eustachian tube (which helps with pressure and balance)

For some patients, this damage doesn’t go away when the infusions stop. That’s part of what makes Tepezza-related hearing loss so concerning. It’s not always mild, and it’s not always temporary.

Most at Risk for Hearing Loss from Tepezza

Not everyone who takes Tepezza ends up with hearing problems, but certain people do seem to be at higher risk. Here are some of the common factors that may raise the chances of hearing damage during or after treatment:

  • Age 65 or older: Older patients are more likely to experience hearing issues, and when they do, it’s often more severe or longer lasting.
  • Preexisting ear or hearing problems: If you already had tinnitus, hearing loss, or inner ear trouble before starting Tepezza, your chances of developing new or worsening symptoms may be higher.
  • Other medications that affect hearing: Some drugs, like certain antibiotics or chemotherapy treatments, are known to harm the ears. Taking these at the same time as Tepezza might make things worse.
  • Graves’ disease and thyroid conditions: Some forms of thyroid disease are already linked to hearing problems on their own, even without Tepezza. The combination may increase your risk.
  • Number of infusions received: Many patients report that symptoms started around the fourth to sixth dose, suggesting that hearing damage may build up over time with continued treatment.

If you or someone you care about is dealing with hearing issues after Tepezza, it’s not always easy to pinpoint the cause, but these patterns are showing up across more and more studies.

Tepezza Hearing Loss Lawsuits

In 2022, the first patients started filing lawsuits after losing some or all of their hearing following Tepezza infusions. They weren’t warned. No one told them this treatment for thyroid eye disease could leave them with lasting hearing problems.

The first known case, Weibel v. Horizon Pharmaceuticals, was filed in August 2022 in Illinois. Another case, Nethery v. Horizon, came just a few weeks later. Since then, more people have stepped forward, and that number is only expected to grow.

So, what are these lawsuits actually saying?

  • Patients say they weren’t warned: Horizon didn’t give clear information about the risk of hearing loss, even though there were signs it was happening.
  • The marketing downplayed the risks: Tepezza was presented as a breakthrough, but the possibility of long-term hearing damage wasn’t part of the message.
  • They didn’t run enough safety tests: Some believe Horizon should have done more to understand how the drug might affect hearing.
  • They delayed follow-up studies: The FDA had asked for more research on long-term side effects, but Horizon didn’t act right away.

Eventually, in 2023, the FDA updated Tepezza’s label to include the risk of permanent hearing loss. But for a lot of patients, the damage had already been done.

These lawsuits are about accountability. The people filing them are asking for help covering the costs of hearing aids, doctor visits, lost income, and the everyday challenges that come with living with hearing damage.

Get Free Consultation

Is There a Tepezza Hearing Loss Class Action?

No, there isn’t a Tepezza class action lawsuit for hearing loss. But there is a large group of individual lawsuits that have been pulled into one place under what’s called multidistrict litigation—also known as MDL 3079, Tepezza Marketing, Sales Practices, and Products Liability Litigation.

This MDL is basically a way to manage similar cases more efficiently. All the lawsuits involve people who took Tepezza to treat thyroid eye disease and later developed hearing issues—things like tinnitus, muffled hearing, or even permanent hearing loss. Instead of handling each case completely separately in courts across the country, they’re being coordinated in the U.S. District Court for the Northern District of Illinois under Judge Thomas M. Durkin.

As of mid-2025, there are more than 210 cases in the MDL, and the number keeps growing. The claims are pretty consistent: patients say Horizon Therapeutics didn’t properly warn about the risk of serious ear-related side effects. Some also argue the company waited too long to start safety studies the FDA required after the drug hit the market.

Right now, both sides are still in the discovery phase—exchanging documents, taking depositions, and building their arguments. The first test trials, called bellwethers, are set to begin in April 2026. These early trials won’t decide every case, but they’ll help set the tone for future settlements or verdicts.

If you’ve experienced hearing problems after using Tepezza, your claim would most likely be part of this MDL, the main legal avenue for patients seeking compensation.

Tepezza Lawsuit Updates as of May 2025

Here’s the latest updates in the Tepezza hearing loss litigation:

  • May 1, 2025: The number of active Tepezza lawsuits has grown slightly to 217, up from 213 last month. This small uptick comes right after the court rejected Horizon’s push to dismiss all cases.
  • April 9, 2025: The judge denied a request from plaintiffs to add more depositions. They wanted to question six Patient Access Liaisons and one Horizon sales rep—people who had direct contact with patients. But the court said the request came too late, since Horizon had named these employees back in August 2023. With the 30-deposition cap still in place and discovery almost done, the judge wouldn’t allow changes this late.
  • April 1, 2025: The MDL now includes 207 lawsuits, up slightly from 203 in early March. While growth is slow, all eyes are on the bellwether trials set to begin in March 2026. Both sides are now working to narrow down which cases will be part of that first round.
  • March 25, 2025: The bellwether trials are scheduled to run between April and September 2026. These early trials won’t decide every case, but they’ll give both sides a better sense of how juries might respond—and could push Horizon toward settlement if the plaintiffs do well.
  • March 4, 2025: The MDL holds steady at 207 cases, up slightly from 203 last month. New filings continue at a slow but steady pace.
  • January 11, 2025: Only 9 new lawsuits were filed in December, following 11 in November. That brings the total to 200 cases in the MDL as of early January.
  • December 30, 2024: A key hearing is set for January 28, 2025, to decide which bellwether cases will move forward. Twelve cases were selected earlier for initial discovery—now three will be chosen for deeper review and trial prep.
  • December 2, 2024: November saw 11 new cases added, compared to just 2 in October—a sharp increase. While the total number of lawsuits remains small, this jump signals growing momentum.
  • November 13, 2024: The judge sided with the plaintiffs, calling out Horizon’s legal team for repeatedly interrupting depositions. The court reminded both sides that discovery should move forward fairly and efficiently.
  • November 4, 2024: Plaintiffs accused Horizon’s lawyers of using long, unnecessary objections during a key deposition to slow things down and influence testimony. A motion was filed to prevent further interference.
  • November 1, 2024: Just two new cases were filed in October, bringing the total to 180. Fewer claims could mean faster progress and potentially stronger settlement offers for those already in the MDL.
  • October 29, 2024: One of the original 12 bellwether cases was dismissed. The judge applied Michigan law, which once protected drugmakers if the FDA approved a product. Even though that law has since been repealed, it still applied to this case.
  • October 18, 2024: A new case from Oklahoma says the plaintiff suffered permanent hearing loss after using Tepezza from November 2022 to February 2023—months before the warning label was updated. The Tepezza lawsuit says Horizon knew about the risks but didn’t act in time.
  • October 1, 2024: Five new lawsuits were filed in September, bringing the total to 178. While the MDL is still small, fewer cases could help speed up resolutions.
  • September 17, 2024: A Florida woman filed suit claiming Tepezza caused her permanent hearing loss between October 2020 and June 2021—long before the drug’s warning label changed. The Tepezza hearing loss lawsuit also calls out Amgen, Horizon’s parent company, for dragging its feet on safety updates.
  • September 3, 2024: August saw a major jump in filings—33 new cases, the biggest increase so far. That brings the total to 173 and shows more patients may finally be connecting their hearing issues to Tepezza.
  • August 18, 2024: Both sides agreed on how depositions will be handled, splitting them into two phases: some due by February 14, 2025, and the rest by April 10. With cooperation improving and the number of cases still manageable, there’s growing hope for settlements before trials begin in 2026.
  • August 1, 2024: The MDL added 10 new cases in July, bringing the total to 148. Growth remains steady but slow.
  • July 30, 2024: Horizon filed a motion to dismiss all lawsuits, though it’s not expected to succeed. Meanwhile, both sides are working out how many depositions will be allowed and how broad they’ll be. A report is due to the judge this week.
  • July 18, 2024: Settlement talks are underway this month. It’s too soon to tell how productive they’ll be, but it’s a step in the right direction.
  • July 14, 2024: Trial dates are now set. Four bellwether trials will start on March 9, May 4, June 29, and August 24, 2026. There’s also growing talk of a possible early settlement, especially since the MDL is still relatively small.
  • July 1, 2024: Nineteen new cases were added in June, including one from a Colorado woman who says she suffered severe hearing loss after three Tepezza infusions in mid-2022. Her suit claims Horizon ignored early warnings from studies and patient reports.
  • June 5, 2024: The court confirmed that the four bellwether trials will take place between March and August 2026.
  • June 3, 2024: Only seven new lawsuits were filed in May, bringing the total to 120. The pace has slowed compared to April.
  • June 2, 2024: Horizon submitted its four bellwether case picks—all of them women.
  • May 20, 2024: The first bellwether trial is locked in for March 9, 2026. Both sides were told to outline how discovery and trial prep should move forward.
  • April 13, 2024: A status hearing scheduled for April 22 was canceled. Instead, both sides must submit a joint report by April 24. The next in-person hearing is set for May 1, 2024.
  • April 9, 2024: A Florida man filed suit after suffering hearing loss and tinnitus from Tepezza infusions in 2022. He says neither he nor his doctors were warned, and no hearing tests were recommended.
  • April 1, 2024: Eight new cases were added in March, pushing the total to 101. That’s nearly double the number since the MDL launched in August 2023 with just 54 cases.
  • March 19, 2024: Oral arguments are set for tomorrow on Horizon’s request to delay bellwether trials. A decision is expected soon.
  • March 13, 2024: Horizon is asking for more time to select its bellwether cases, saying it needs longer to review records. Plaintiffs are expected to push back.
  • March 1, 2024: A new treatment for thyroid eye disease may be on the way. IBI311, a drug from Innovent Biologics, just finished a successful trial in China and may be approved there soon. U.S. approval could follow.
  • February 15, 2024: Both sides are still arguing over how to handle certain data. If they can’t agree, they’ll submit separate plans to the judge by February 28. The court will review them on March 6.
  • February 8, 2024: Horizon won’t finish producing key documents until late 2024, delaying progress. Plaintiffs believe those records—emails, reports, meeting notes—will be crucial to showing what Horizon knew and when.
  • January 15, 2024: Three new lawsuits were filed since mid-December, bringing the total to 74 (or 75, counting Ingram v. Horizon). The small size of this MDL could work in plaintiffs’ favor when it comes to settlement.
  • January 9, 2024: Both sides asked for 60 more days to finish choosing their bellwether cases. The extension would help them review medical records and pick the strongest claims.
  • January 8, 2024: Six months into the MDL, progress is slow. Horizon tried to cancel the next status hearing, claiming there’s nothing to discuss, but plaintiffs pushed back, citing unresolved issues like production protocols.
  • December 18, 2023: Twelve new cases were added this month, bringing the total to 71—twice as many as last month. This could be the start of a bigger wave in early 2024.
  • December 1, 2023: A new discovery dispute is brewing. Plaintiffs filed a submission outlining concerns about how Horizon is handling its early discovery duties. The issue will likely be addressed at an upcoming hearing.
  • November 20, 2023: A Florida woman joined the MDL, claiming she developed permanent hearing loss and tinnitus after receiving Tepezza infusions between August 2022 and April 2023. She says she and her doctors were never warned about the risks.
  • November 19, 2023: Only five new lawsuits were added in the past month, bringing the total to 59. While growth is slow, that could work in favor of early plaintiffs by speeding up resolution.
  • November 6, 2023: A major ruling went in favor of the plaintiffs. The judge allowed a design defect claim to move forward, rejecting Horizon’s argument that federal law overrides state law. This means plaintiffs can argue Horizon should’ve developed a safer version of Tepezza from the start.
  • November 3, 2023: The court issued a Case Management Order for selecting bellwether cases. Each side will choose four, and the court will randomly pick another four—twelve total. These cases will move into discovery to prep for trial.
  • September 18, 2023: The MDL has grown from 41 cases in June to 54 by mid-September. It’s not a huge jump, but filings are expected to rise as more patients connect their hearing issues to Tepezza.
  • September 14, 2023: Magistrate Judge M. David Weisman is now overseeing discovery. He’ll manage deadlines, help with settlements, and hold a status hearing on September 19, 2023.
  • September 11, 2023: Amgen’s $27 billion acquisition of Horizon is moving forward after clearing FTC objections. This matters because Amgen now inherits liability for Tepezza lawsuits—and it has the resources to pay out if settlements are reached.
  • September 10, 2023: At a September 8 hearing, the judge instructed both sides to finalize a protective order and agreement on privileged materials. These will allow Horizon to share key documents during discovery without waiving confidentiality.
  • September 1, 2023: Plaintiffs proposed a faster bellwether schedule: pick six cases, do 150 days of focused discovery, then choose three for trial. Horizon, meanwhile, wants a larger pool of 10 cases.
  • August 18, 2023: A Florida woman filed Mhamdi v. Horizon Therapeutics directly in the MDL, claiming she now suffers from hearing loss after using Tepezza between 2020 and 2023. She says no one warned her of the risks.
  • August 15, 2023: Five more lawsuits were added, raising the case total to 46. At this pace, the MDL could hit 100 cases by year’s end—and it did, with 73 cases filed by December.
  • August 2, 2023: Just three new cases were filed in July, but June saw a record 16. The pace of filings is uneven, but momentum is slowly building.
  • July 25, 2023: As more lawsuits pile up, scrutiny of Horizon is increasing. The FDA has updated Tepezza’s label to warn about the risk of permanent hearing damage.
  • June 19, 2023: The first Tepezza MDL status conference is scheduled for June 28, 2023. It’ll give Judge Durkin a chance to lay out how the case will move forward and assign leadership roles to the plaintiffs’ attorneys.
  • June 5, 2023: The MDL is officially underway. Plaintiffs allege Horizon failed to warn about serious hearing-related side effects. Judge Durkin in Chicago is overseeing the litigation.
  • May 31, 2023: A new Tepezza lawsuit was filed in Ohio by a woman who says she developed hearing loss after Tepezza infusions in 2021. She says she was never warned of the risks.
  • May 22, 2023: The JPML is preparing to hear arguments on whether to consolidate Tepezza lawsuits into an MDL. Meanwhile, the FTC has temporarily blocked Amgen’s deal to buy Horizon.
  • May 11, 2023: The JPML will decide on May 25 whether to centralize Tepezza hearing loss lawsuits. Horizon is fighting the move, saying the number of cases isn’t high enough yet.
  • May 8, 2023: More lawsuits are being filed. Since the MDL request in March, seven new cases have been added. The JPML will decide soon whether to consolidate them under one judge.
  • April 26, 2023: The JPML will meet on May 25 to decide if Tepezza cases should be centralized in an MDL. If approved, it would streamline the process and help avoid conflicting rulings.
  • April 14, 2023: Despite rising lawsuits, Horizon is still growing Tepezza’s market. The FDA approved expanded use of the drug for treating Thyroid Eye Disease, following a Phase 4 trial showing strong results. Horizon plans to present the data at medical conferences. Bottom line: even with lawsuits, Tepezza remains a major moneymaker.
  • April 13, 2023: A formal motion was filed to consolidate all federal Tepezza lawsuits into an MDL. It listed 18 cases filed across five federal courts and proposed the Northern District of California as the venue.
  • April 4, 2023: A new Stanford case study adds to concerns about Tepezza and hearing loss. A 64-year-old woman lost hearing after a full course of treatment in 2021. When given a lower dose later on, the hearing issues didn’t return—suggesting a possible link between dosage and side effects.
  • March 24, 2023: Four more Tepezza hearing loss lawsuits were filed in March, raising the total to 34. Thirteen of those have already been voluntarily dismissed, possibly due to early settlements.
  • February 28, 2023: Tepezza lawsuits generally claim that patients weren’t warned about the risk of permanent hearing loss or tinnitus. Most suits allege failure to warn, product liability, and, in some cases, seek punitive damages for negligence.
  • February 14, 2023: Horizon is trying to dodge liability by arguing that the FDA—not the company—controls warning labels. This preemption defense is common, but courts sometimes reject it, especially if there’s proof Horizon could’ve pushed for stronger warnings.
  • January 20, 2023: Plaintiffs asked to consolidate 10 hearing loss cases in the Northern District of Illinois as a local MDL to streamline the process. Horizon opposed the move, saying the cases are too different to be grouped together.
  • January 18, 2023: Amgen announced its plan to acquire Horizon for $116.50 per share. But some Amgen investors filed suit to block the sale, claiming Horizon failed to disclose known risks about Tepezza and hearing damage. Even major players are starting to take notice.

Who Can File a Tepezza Hearing Loss Lawsuit?

You may qualify to file a Tepezza lawsuit if:

  • You were treated with Tepezza (teprotumumab) between January 2020 and today 
  • You used the drug for thyroid eye disease (TED) or any of its related diagnoses, including:

  • Graves’ eye disease 
  • Graves’ orbitopathy 
  • Graves’ ophthalmopathy

And afterward, you developed hearing problems, such as:

  • Hearing loss (partial or complete) 
  • Tinnitus (ringing or buzzing in the ears)

Even if your symptoms started mild, if they lingered—or worsened—after your infusions, you could have a case. A Tepezza lawyer can help review your records and determine what steps to take next.

What Kind of Compensation Can You Get?

If Tepezza affected your hearing, you might be able to recover money for what you’ve gone through—physically, financially, and emotionally. This can include:

  • Bills from hearing tests, audiologist visits, or hearing aids 
  • Wages you lost if your condition kept you from working 
  • The stress, frustration, or day-to-day struggles caused by the hearing issues 
  • Permanent hearing damage that affects how you live your life 
  • Out-of-pocket costs for devices or changes to your home or job to help you adapt

These lawsuits are about everything you’ve had to deal with since.

Get Free Consultation

How Much Time Do I Have to File a Tepezza Injury Lawsuit?

Every state has a deadline for filing a Tepezza lawsuit, and it usually starts when you first notice the problem. In Pennsylvania, you generally have two years from the time you noticed your hearing issues. If you think Tepezza caused your hearing loss, talk to a Tepezza lawyer soon to protect your rights.

Ethen Ostroff Law: Now Taking Tepezza Hearing Loss Cases

People who’ve developed hearing issues after Tepezza infusions are starting to come forward—and we’re here to help. At Ethen Ostroff Law, we’re currently reviewing these cases and working with individuals who may have been affected.

We’ll walk you through your options, figure out if you qualify, and help build your case. That includes gathering records, calculating damages, and making sure everything is filed on time. If needed, we’re ready to take your case to trial.

Throughout the process, we’ll keep you updated and stay available to answer your questions. If Tepezza affected your hearing, reach out for a free case evaluation.

Frequently Asked Questions

Yes, there are several lawsuits filed by patients who say Tepezza caused serious hearing issues, including hearing loss and tinnitus. These cases have been grouped together in a federal MDL (multidistrict litigation) in Illinois to make the legal process more efficient. As of mid-2025, more than 230 cases are pending, and early trials are set to begin in 2026.

Tepezza is under fire because many patients reported hearing problems after treatment—some temporary, others permanent. People are saying they weren’t warned about these risks until after they started having symptoms. The main issue is that the warnings came too late, and patients feel they were left in the dark about how serious the side effects could be.

Settlement amounts can vary, but some early estimates suggest payouts could range from around $75,000 to $350,000, depending on how severe and lasting the hearing damage is. More serious cases—like permanent hearing loss—may be worth more. Since the lawsuits are still in progress, no final amounts have been set yet.

Tepezza Lawyer

If you want a lawyer who cares about you and the outcome of your tepezza lawsuit, choose Ethen Ostroff. He and his professional connections ensure you get every dollar possible for what you went through.

While in law school, he distinguished himself as Executive Editor of JURIS Magazine, received the prestigious CALI Excellence for the Future Award, and completed five hands-on internships that laid a strong foundation for his legal career.


Nicholas began his post-graduate career clerking for the Honorable Linda Rovder Fleming in the Cambria County Court of Common Pleas. From there, he quickly found his calling in workers’ compensation, personal injury, and Social Security disability law—areas where he could directly impact people’s lives in moments of crisis. He’s helped clients navigate complex legal claims, including securing a settlement exceeding $300,000.

Nicholas brings clear communication, genuine empathy, and an unrelenting drive to achieve the best outcomes for his clients. Whether he’s navigating a complex workers’ comp claim or pushing for a major settlement, he brings focus, dedication, and deep legal knowledge to every case.

He’s also a proud member of Pennsylvania Advocates for Justice and remains active in various professional legal organizations. Nicholas is licensed to practice law in Pennsylvania.

When he’s not fighting for the injured, Nicholas is enjoying time with his family, kicking a soccer ball around, hitting the golf course, or cheering on Pittsburgh’s local teams.

Joe Ring heads the workers’ compensation department at Ethen Ostroff Law, where he takes pride in fighting for injured workers.

Joe is a Philadelphia native and maintains deep roots in the area.  As the grandson of a Philadelphia Firefighter, son of a Philadelphia public school teacher, and veteran of the United State Marine Corps, he was taught to value service, dedication, and hard work.   He applies these values to every case and takes great satisfaction in representing hard-working clients with those same traits.

After obtaining his bachelor’s degree in history from St. Vincent College in Western Pennsylvania, he graduated from Villanova Law School in 2012 and, since then, has litigated hundreds of workers’ compensation hearings and trial depositions on behalf of both employers and injured workers.  During this time, Mr. Ring has written articles and presented Continuing Legal Education courses on developments in Pennsylvania Workers’ Compensation Law.  He is active in local professional organizations, and, in 2022, he served a Co-chairperson of the Philadelphia Bar Associations Workers’ Compensation Section.

Since coming to EOL in 2024, he has dedicated his practice entirely to helping injured workers navigate the system and obtain their rightful benefits.

Joe is licensed to practice in Pennsylvania.

Brandon Zanan heads the personal injury claim department with Ethen Ostroff Law.

Brandon’s education in both law and medicine assist him in expertly representing badly injured victims. Brandon has a Master’s Degree in Forensic Medicine from the Philadelphia College of Osteopathic Medicine, with a concentration in anatomy and pathology. With this knowledge,  Brandon is skilled at analyzing medical records and understanding injuries that are common in personal injury claims. He uses this expertise in conjunction with listening carefully to each client’s needs, in order to fiercely advocate for clients and tell their stories when they would not otherwise have a voice.

Brandon’s background includes a variety of experience and skills in various areas of civil practice. He is the author and editor of numerous books for the George T. Bisel Publishing Company, including “Pennsylvania Damages” and the “Pennsylvania Vehicle Code Annotated,” two texts that are frequently relied on by lawyers and judges across Pennsylvania as authoritative resources on personal injury law.

Brandon is a member of the Pennsylvania and Montgomery Bar Associations. He is also a member of Pennsylvania Association for Justice, and has served as an executive board member of the Montgomery American Inn of Court.

He is admitted to practice in the Commonwealth of Pennsylvania, the United States District Courts for the Eastern District of Pennsylvania and Middle District of Pennsylvania, the State of New Jersey, the United States District Court for the District of New Jersey, and in the Commonwealth of Virginia. Brandon has represented many clients in motor vehicle, premises liability, animal bite, and products liability cases across Pennsylvania and New Jersey and has obtained outstanding results with millions of dollars recovered for his clients.

He has been named a Pennsylvania Rising Star from 2021 onward. The “Super Lawyers-Rising Star®”, list recognizes no more than 2.5 percent of attorneys in each state

Brandon currently lives in Malvern with his wife Rachel and their son Max.

Ethen Ostroff Law, PLLC Terms and Conditions

Effective Date: July 10, 2024

General Information

Welcome to the website of Ethen Ostroff Law, PLLC (“EO”). By accessing or using our website, you agree to be bound by these Terms and Conditions (“Terms”). If you do not agree with these Terms, please do not use our website.

Use

EO hereby grants you a non-exclusive, non-transferable, revocable, limited right and license to access and use the Site solely for your personal use in accordance with these Terms of Use. You shall not, in any way, otherwise copy, reproduce, distribute, transmit, display, perform, reproduce, publish, license, modify, create derivative works from, sell, or exploit the Site.

EO may at any time, for any reason, and without notice or liability: (a) modify, suspend, or terminate operation of or access to the Site and related services, or (b) change, revise, or modify the Site and affiliated services.

Messaging and Automated Calls

When you opt-in, you will receive text messages (SMS/MMS) on your mobile number. These messages may contain information about your case, and the message frequency may vary from user to user. Please note that message and data rates may apply. If you wish to opt out of this service, you can do so anytime by simply texting “STOP” to the phone number. Once you text “STOP” to us, we will send you an SMS to confirm that you have been unsubscribed. If you encounter any issues, you can reply with the keyword “HELP” to get assistance. Please be aware that carriers are not responsible for any delayed or undelivered messages.

By providing your phone number and submitting a form on our website, you consent to receive communications, including automated calls, texts, and pre-recorded messages, from EO and its affiliates. These communications may include updates about your case, promotional offers, and other information. You understand that these calls may be generated using automated technology, and that standard message and data rates may apply.

Your consent to receive automated calls is not a condition of any purchase or service. By checking the consent box on our contact form or by calling our firm, you agree to these Terms and Conditions and provide your written consent to receive these communications. You may opt out of these communications at any time by replying STOP to any text message or by contacting us at [insert contact information].

State-Specific Compliance

EO complies with all federal and state laws regarding automated calls and telemarketing practices. Certain states have additional restrictions on the use of automated dialing systems and pre-recorded messages. The following states have more restrictive regulations:

  • California: Requires prior express written consent for automated calls.
  • Florida: Requires prior express written consent for automated calls and texts.
  • New York: Requires prior express written consent for automated calls.
  • Texas: Requires prior express written consent for automated calls.

If you are a resident of one of these states, EO will obtain your prior express written consent before making any automated calls or sending pre-recorded messages to you.

By submitting a form inquiry or calling our firm, you agree to us contacting you, and your checking the box when submitting your form inquiry serves as written consent.

Information and Legal Disclaimer

The information contained in this website is for informational purposes only, and should not be construed as legal advice. Testimonials and case results contained in this website are for demonstrative purposes only, and do not constitute a guarantee of any particular outcome in a specific case.

By requesting a free consultation with Ethen Ostroff Law, PLLC, you agree to the following:

  • Any information I submit is for review only, and there will be no charge for the initial consultation.
  • I have not entered into an attorney-client relationship with Ethen Ostroff Law, PLLC until such time as a formal written Retainer Agreement is signed by myself and a representative of Ethen Ostroff Law, PLLC. There is no guarantee that Ethen Ostroff Law, PLLC will accept my case.
  • Any information received by Ethen Ostroff Law, PLLC, prior to the execution of a written Retainer Agreement, is not subject to the Attorney-Client Privilege and is not considered confidential.
  • Additional information may be requested in order for Ethen Ostroff Law, PLLC to make a decision on whether or not to accept my case.
  • Because no attorney-client relationship has been established, I will remain personally responsible to meet all necessary deadlines applicable to my claim, until such time as Ethen Ostroff Law, PLLC makes a final decision. I acknowledge that I have not received any representations or legal opinions with respect to any time frames or deadlines that may be applicable to my claim.

No Relationship or Obligation Arises from Use of the Site

The law differs in every jurisdiction, and you should not rely on any opinion except that of an attorney you have retained, who has a professional duty to advise you after being fully informed of all the pertinent facts, and who is licensed in the applicable state, and is familiar with the applicable law. Internet subscribers, mobile application users, and online readers should seek professional counsel about their legal rights and remedies. You should not act or refrain from acting on the basis of any information found on the Site. Any actions or decisions about your legal rights should be based on the particular facts and circumstances of your situation, and appropriate legal advice from an attorney retained directly by you. EO EXPRESSLY DISCLAIMS ALL LIABILITY WITH RESPECT TO ACTIONS TAKEN OR NOT TAKEN BASED UPON ANY INFORMATION OR OTHER CONTENTS OF THIS SITE. Viewing the Site, or communicating with EO by Internet e-mail or through the Site does not constitute or create an attorney-client relationship with anyone. The content and features on the Site do not create, and are not intended to create, an attorney-client relationship, and shall not be construed as legal advice. The content and features of the Site, including means to submit a question or information, do not constitute an offer to represent you or otherwise give rise to an attorney/client relationship.

THE SITE IS PROVIDED “AS IS”. EO MAKES NO WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE SITE AND ONLINE SERVICES AND HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND OR NATURE, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, EO DOES NOT GUARANTEE THAT THE ONLINE SERVICES OR PRODUCTS WILL MEET YOUR REQUIREMENTS, OR WILL BE ERROR-FREE, UNINTERRUPTED, OR FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS, OR THAT ANY DEFECTS WILL BE CORRECTED.

Accounts

To use some features of the Site, you may be required to create an account. In connection therewith, you agree to provide and maintain true, accurate, current, and complete information about yourself. You are responsible for maintaining the confidentiality of the information you hold for your account login, including your password, and for all Submissions made from your account. You agree to notify us immediately of any unauthorized use of your login. EO may suspend access to your account if it suspects illegal or improper use, or for other reasons, such as for account management purposes, at its sole discretion.

Confidentiality is Not Guaranteed

Information sent to Ethen Ostroff Law, PLLC. via Internet e-mail or through the Site is not secure and is done on a non-confidential basis. EO may make reasonable efforts to keep communications private, but because of the nature of Internet communications and the absence of an attorney/client relationship, we cannot promise or guarantee confidentiality.

DISCLAIMER – This Site Does Not Provide Medical Diagnosis or Advice

The content provided on the Site, such as documents, text, graphics, images, videos, news alerts, pharmaceutical drug recalls, prescription medication history, or information on litigation concerning the foregoing topics, or other materials, is for informational purposes only. The information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a physician for diagnosis and treatment of any medical condition or for any questions you may have regarding a health concern. Never disregard professional medical advice, alter a prescription plan in any way, or delay or refrain from seeking medical advice because of something you have read or seen on the Site. Links to other sites are provided for information only. Use of trade names is for identification only and does not constitute endorsement by EO.

Without limiting the generality of the foregoing, the Site may present information about pharmaceutical drug recalls, which is for information purposes only. Such information is not necessarily the most current information on the subject and may or may not be updated based on the last information concerning such recalls. Do not make any decisions regarding medication or medical providers based on information from the Site, including but not limited to information we provide about drug recalls.

EO Is Not Responsible for Content; Limitation on Liability

EO may periodically change, remove, or add the material on the Site without notice. This material may contain technical or typographical errors. EO DOES NOT GUARANTEE ITS ACCURACY, COMPLETENESS OR SUITABILITY. EO assumes no liability or responsibility for any errors or omissions in the contents of the Site. Your use of the Site is at your own risk. Under no circumstances shall EO or any other party involved in the creation, production, or delivery of the Site be liable to you or any other person for any indirect, special, incidental, or consequential damages of any kind arising from your access to, or use of, the Site. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW IN NO EVENT SHALL EO BE LIABLE FOR ANY SPECIAL, INDIRECT, OR CONSEQUENTIAL DAMAGES RELATING TO THIS MATERIAL, FOR ANY USE OF THIS WEBSITE, OR FOR ANY OTHER LINKED WEBSITE.

Third-party Web Sites

The Site contains links to third-party websites for the convenience of our users. EO does not endorse any of these third-party sites and does not imply any association between EO and those sites. EO does not control these third-party websites and cannot represent that their policies and practices will be consistent with these Terms of Use. If you use links to access and use such websites, you do so at your own risk. EO is not responsible for the contents or availability of any linked sites. These links are provided only as a convenience to the recipient. These Terms only apply to the Site and do not apply to any linked sites. We encourage you to read and understand the terms of use of any linked sites that you visit. Links do not imply that we sponsor, endorse, are affiliated with or associated with, or are legally authorized to use any trademark, trade name, service mark, design, logo, symbol, or other copyrighted materials displayed on or accessible through any linked site.

EO Clients

Only individuals who have entered into a mutually signed retainer agreement with EO are EO clients (“EO Clients”).

Legal and Ethical Requirements

EO has tried to comply with all legal and ethical requirements in compiling the Site. We welcome comments about our compliance with the applicable rules and will update the Site as warranted, upon learning of any new or different requirements.

Ethen Ostroff Law reserves the right to refer or sell leads that come through any of Ethen Ostroff Law’s marketing.

Ethen Ostroff Law also may sell leads on certain campaigns generated in association with third party marketing companies.

Governing Laws in Case of Dispute; Jurisdiction

These Terms of Use shall be governed by and construed in accordance with the laws of the State of Pennsylvania, USA, without regard to any choice of law principles. Any and all disputes arising hereunder shall be governed as set forth in the Arbitration section below.

Submissions

You are solely responsible for any information, content, or material you transmit to or through the Site (“Submissions”). You understand that Submissions are considered non-confidential and non-proprietary. Furthermore, you grant EO an unrestricted, irrevocable, perpetual, transferable, sublicensable, worldwide, royalty-free license to use, copy, reproduce, display, publish, publicly perform, transmit, and distribute any Submission, without compensation or accounting to you or anyone else. You represent and warrant that: (a) you have the right to submit the Submission to EO and grant the licenses as described above; (b) EO will not need to obtain licenses from any third party or pay royalties to any third party for its use of the Submission; (c) the Submission does not infringe any third party’s rights, including intellectual property rights and privacy rights; and (d) the Submission complies with these Terms of Use and all applicable laws and regulations.

EO takes no responsibility and assumes no liability for any Submission.

Arbitration

Any and all claims by you arising out of or related to the Site or your use thereof may be resolved only through a binding arbitration proceeding to be conducted under the auspices of the Commercial Arbitration Rules of the American Arbitration Association in Montgomery County, Pennsylvania. Both your agreement to arbitrate all controversies, disputes and claims, and the results and awards rendered through the arbitration, will be final and binding on you and may be specifically enforced by legal proceedings. Arbitration will be the sole means of resolving such controversies, disputes and claims, and you waive your rights to resolve such controversies, disputes and claims by court proceedings or any other means. You agree that judgment may be entered on the award in any court of competent jurisdiction and, therefore, any award rendered shall be binding. The arbitrator may not consolidate more than one person’s claims, and may not otherwise preside over any form of a representative or class proceeding. You understand that by agreeing to arbitration as a mechanism to resolve all controversies, disputes and claims between us, you are waiving certain rights, including the right to bring an action in court, the right to a jury trial, the right to broad discovery, and the right to an appeal. You understand that in the context of arbitration, a case is decided by an arbitrator (one or more), not by a judge or a jury.

International Use

The Site is controlled, operated, and administered by EO from offices within the United States of America and is only intended for use therein. We make no representation regarding use of the Site outside of the United States.

Other Terms

If, for any reason, our Terms of Use, Privacy Policy, or any portion thereof to be unenforceable, such provision shall be enforced to the maximum extent permissible so as to give the intended effect thereof, and the remainder of these Terms of Use and Privacy Policy shall continue in full force and effect. EO’s failure to act with respect to a breach by you or others does not waive our right to act with respect to that breach or subsequent or similar breaches. No consent or waiver by EO hereof will be deemed effective unless in writing. These Terms of Use, together with our Privacy Policy, as each is currently posted, constitute the entire agreement between EO and you with respect to your use of the Site and supersede all previous written or oral agreements relating to the subject matter hereof, that this agreement shall not supersede, restrict, or replace any agreements governing the attorney-client relationship between EO and EO Clients.

EO may, in its sole discretion and without prior notice, block and/or terminate your access to the Site and if we determine that you have violated these Terms of Use or other terms or agreements or that may be associated therewith or if you use the Site in a way that we deem, in our sole discretion, to be an unacceptable use.

Get Your Free Case Review

Find out if you qualify for compensation and learn your next steps – no cost, no obligation, just expert legal guidance.

Disclaimer: By submitting the form above and checking the consent box, you agree to our conditions and privacy policy and permit Ethen Ostroff Law to contact you via text messages, phone calls. Standard message rates may apply.